
SHS buys minority stake in Develco Pharma
SHS has acquired a minority stake in Germany-based drug developer Develco Pharma.
The investment is intended to accelerate the company's development of new drugs, according to a statement. New products are likely to focus on new indications and therapeutic areas.
The deal came about via a proprietary connection, with an introduction taking place at the start of 2020, Manfred Ulmer-Weber, partner at SHS, told Unquote: "We were able to meet before the lockdown started and saw that it could be an interesting situation for both parties. Develco is well established and has a strong growth pipeline, and as a specialised healthcare investor, we were able to bring not just money but also value to the table."
Ulmer-Weber is to join Develco's board of directors following the transaction, according to a statement.
SHS is investing via its fifth fund, which held a final close in July 2019 on €130m and has now made nine investments. The vehicle generally deploys equity tickets of up to €30m, with the option to provide up to €60m alongside co-investors. The fund focuses on healthcare, medical technology and diagnostics businesses.
The fund aims to make 12-15 deals in total, Ulmer-Weber said, and he expects the vehicle will make around five more deals in 2021 and 2022: "We are looking for growth cases and buyouts; we still have some dry powder in our fund."
Company
Develco provides development, approval and production of innovative and generic pharmaceutical products. The company also has a modular system of formulation technologies to manufacture orally administered drugs. Develco's client base comprises pharmaceutical companies that sell products on a global scale.
Develco was founded in 2006 and employs 120 staff. It is headquartered in Schopfheim, Germany, and also has operations in Switzerland.
People
SHS – Hubertus Leonhardt (partner, managing director); Manfred Ulmer-Weber (partner).
Develco Pharma – Mathias Scheer (chairman of the board of directors); Martin Renner (CEO).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater